2.5mg Mounjaro: the starting dose most people misread

The biggest myth: 2.5mg should produce weight loss

The most common misunderstanding about the 2.5mg dose is that it should be working, shrinking appetite, driving weight loss, showing something on the scales. Patients search for reassurance that they are not just injecting saline. The clarification that tends to land best is this: the dose is intentionally sub-therapeutic. Eli Lilly designed the starting schedule this way because tirzepatide, as a dual GIP and GLP-1 receptor agonist, slows gastric emptying and changes gut-hormone signalling quite significantly. Going straight to a higher dose would, for most people, mean a brutal first few weeks of nausea, vomiting or constipation severe enough to make them stop.

So 2.5mg serves a physiological purpose: it introduces the mechanism gradually. Your system starts recognising the drug without being overwhelmed by it. Some people do notice a modest appetite reduction even at this stage, and a small amount of early weight change is possible, but the NHS tirzepatide guidance does not describe 2.5mg as a weight-management dose. Expecting clinical results at this stage sets up a frustration that has nothing to do with how your body will ultimately respond. Patience here pays off later.

If you are trying to understand the full dose ladder and where 2.5mg sits within the Mounjaro schedule, the Mounjaro dose comparison chart sets out all six UK strengths in context.

What the 2.5mg pen actually contains and how it works

Mounjaro is supplied in a pre-filled KwikPen. Each pen holds four doses, meaning one 2.5mg pen covers exactly four weekly injections, the full starter period. You inject once a week into your abdomen, thigh or upper arm, rotating the site each time. The pen itself is compact, and when it arrives from a GPhC-registered pharmacy it comes in plain, unbranded packaging; DPD delivers it tracked to your door the next working day, so you know exactly when to expect it.

The pen needs to be stored in the fridge between 2°C and 8°C. There is a limited window during which it can be kept at room temperature, the exact number of days is stated in the Patient Information Leaflet that comes with your treatment, and that is always the authority to follow rather than any general figure online. The Mounjaro 2.5mg pen page covers the practical handling detail in full.

Tirzepatide works by activating two receptors (GIP and GLP-1) involved in appetite regulation and blood-sugar control. Even at 2.5mg, the mechanism is present. The dose is low enough to be gentle; it is not zero. Some patients notice they feel slightly fuller sooner at meals. For others the four weeks pass with almost no noticeable change at all, which is also fine. The starter dose is doing its job quietly.

Moving from 2.5mg: when and how the step happens

After four weeks, most patients move to the 5mg dose. That transition is a clinical decision, not an automatic switch. Your prescriber reviews how you tolerated the starter period (gastrointestinal symptoms, any other reactions, your overall response) before confirming the step up. If tolerability was difficult, a prescriber might recommend staying at 2.5mg for a further four weeks before moving on. That is not a failure; it is the schedule working as intended.

The 2.5mg to 5mg transition is worth reading before your review, because patients often have questions about what to expect when the dose increases. Generally, some of the same early gastrointestinal effects can return briefly at each step, they tend to settle faster than they did at the very start. The 5mg Mounjaro page explains what changes at that stage.

One thing worth knowing: the first meaningful weight-loss results seen in clinical trials correspond to the higher therapeutic doses, not the starter. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants eventually reached doses of 10mg and continued stepping up through intermediate strengths such as 7.5mg on the way to 15mg, with average body-weight reductions of around 20% over 72 weeks. That context matters: 2.5mg is the beginning of a journey that takes months, not weeks, to show its full effect.

Side effects to expect at 2.5mg, and when to seek help

The 2.5mg period is specifically designed to reduce side effects, but it does not eliminate them entirely. The most commonly reported effects in clinical trials were gastrointestinal: nausea, loose stools, constipation, indigestion and burping. These tend to be milder at 2.5mg than at higher doses and often settle within the first week or two of a new dose level. Fatigue, headache and dizziness are also reported by some people, particularly in the first few days.

Most people manage the starter dose without significant disruption. Eating smaller portions, avoiding very fatty or rich food, and staying well hydrated all help. Your prescriber and the 7-day aftercare team can offer guidance if symptoms feel difficult, that support is part of what comes with a properly managed private prescription rather than an unreviewed purchase.

Certain symptoms need prompt medical attention: severe or persistent stomach pain that spreads to the back could indicate pancreatitis, which the MHRA highlighted as a known but infrequent risk in a Drug Safety Update in January 2026. Signs of an allergic reaction (swelling, rash, difficulty breathing) also warrant urgent care. The Patient Information Leaflet in your pack gives the complete list. If you are uncertain about any symptom, speaking to a GP or calling 111 is always the right call. Patients and healthcare professionals can report suspected side effects through the Yellow Card scheme.

If you are considering treatment and want to understand more about the full process, checking your eligibility through a free consultation is the starting point, a prescriber reviews the picture before anything is prescribed.